ATHERSYS, INC.

Biotech · Acquired

MultiStem, an allogeneic bone marrow-derived mesenchymal stem cell therapy for acute respiratory distress syndrome

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $3M

Federal grants: $3M; 5 awards · 2015–2017; Rank in peer group#343 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 20 pending

Capital timeline

Latest events

Aug 2017Federal grantHealth and Human S · Phase II · Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome$294K
Sep 2016Federal grantHealth and Human S · Phase II · Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome$744K
Mar 2016Federal grantHealth and Human S · Phase II · Phase II Trial Evaluating the Safety and Efficacy of an Allogeneic Stem Cell for$843K
Jul 2015Federal grantHealth and Human S · Phase I · Combinatorial Treatment of Acute Spinal Cord Injury with MultiStem Cell Therapy and Intracellular Sigma Peptide$213K
Jan 2015Federal grantHealth and Human S · Phase II · Phase II Trial Evaluating the Safety and Efficacy of an Allogeneic Stem Cell for$866K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 20

PendingThienylindole Azepines As Serotonin 5-HT2C Receptor Ligands And Uses ThereofUSPTOApplication 61780424
PendingPyrazoles For The Treatment Of Obesity And Other Cns DisordersUSPTOApplication PCTUS2007002547
PendingMapc Therapeutics Without Adjunctive Immunosuppressive TreatmentUSPTOApplication PCTUS2007001747

Show all 20 patent records

Thienylindole Azepines As Serotonin 5-HT2C Receptor Ligands And Uses ThereofApplication 61780424Pending
Pyrazoles For The Treatment Of Obesity And Other Cns DisordersApplication PCTUS2007002547Pending
Mapc Therapeutics Without Adjunctive Immunosuppressive TreatmentApplication PCTUS2007001747Pending
Thiophenyl And Pyrrolyl Azepines As Serotonin 5-HT2C Receptor Ligands And Uses ThereofApplication PCTUS2007001345Pending
Indole Derivatives As Histamine 3 Receptor Inhibitors For The Treatment Of Cognitive And Sleep Disorders Obesity And Other Cns DisordersApplication PCTUS2006040744Pending
Culture Of Non-embryonic Cells At High Cell DensityApplication PCTUS2006029547Pending
Use Of A GSK-3 Inhibitor To Maintain Potency Of Cultured CellsApplication PCTUS2006029736Pending
4-PIPERIDINOL Tertiary Amines As Histamine 3 Receptor Inhibitors For The Treatment Of Obesity And Other Cns DisordersApplication PCTUS2005046703Pending
Benzimidazole Acetic Acids Exhibiting CRTH2 Receptor Antagonism And Uses ThereofApplication PCTUS2005034028Pending
Indole Acetic Acids Exhibiting CRTH2 Receptor Antagonism And Uses ThereofApplication PCTUS2005034029Pending
Tricyclic Heteroaryl Piperazines, Pyrrolidines And Azetidines As Serotonin Receptor ModulatorsApplication PCTUS2005031306Pending
Tricyclic Indeno-pyrrole Derivatives As Serotonin Receptor ModulatorsApplication PCTUS2005026415Pending
Cyclic N-hydroxy Imides As Inhibitors Of Flap Endonuclease And Uses ThereofApplication PCTUS2005025592Pending
Non-imidazole Tertiary Amines As Histamine 3 Receptor Inhibitors For The Treatment Of Cognitive And Sleep Disorders, Obesity And Othe Cns DisordersApplication PCTUS2005023290Pending
Substituted Azepine Derivatives As Serotonin Receptor ModulatorsApplication PCTUS2005023282Pending
BENZO(1,3)DIOXOLE Compounds, Pharmaceutical Compositions Thereof, And Processes Of Making And Using The SameApplication PCTUS2004027629Pending
Enhanced Engineered Chromosome Formation From Alpha Satellite With Artificially Increased Density Of Cenp-b BoxesApplication PCTUS2004022314Pending
Methods For Using ADAMTS-12, An Integrin And Metalloprotease With Thrombspondin MotifsApplication PCTUS2003018125Pending
Methods For Mutating Genes In Cells And Animals Using Insertional MutagenesisApplication PCTUS2002035405Pending
Compositions And Methods For Making Mutaions In Cell Lines And AnimalsApplication PCTUS2002033714Pending

InscriptaSimilar federal contract value in Biotech · null in contracts
Mirador TherapeuticsSimilar federal contract value in Biotech · null in contracts
SYNCANICA BIOSimilar federal contract value in Biotech · null in contracts
JuvenescenceSimilar federal contract value in Biotech · null in contracts
REPLICEL LIFE SCIENCES INC.Similar federal contract value in Biotech · null in contracts
Ideaya Biosciences, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.